Provided by Tiger Trade Technology Pte. Ltd.

GRAIL, Inc.

139.55
+6.945.23%
Volume:366.92K
Turnover:51.09M
Market Cap:6.23B
PE:-14.31
High:142.49
Open:133.35
Low:133.31
Close:132.61
52wk High:166.48
52wk Low:41.50
Shares:44.67M
Float Shares:40.73M
Volume Ratio:0.79
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.7487
EPS(LYR):-11.1105
ROE:-16.12%
ROA:-12.03%
PB:2.45
PE(LYR):-12.56

Loading ...

Movement Alert|GRAIL, Inc. Rises 5.56% in Regular Trading, FDA Advisory Committee Favorable Vote Continues to Catalyze

Market Focus
·
2 hours ago

Movement Alert|GRAIL, Inc. Rises 5.14% in Regular Trading, FDA Panel's Positive Vote on Galleri Continues to Drive Momentum

Market Focus
·
Oct 06

Movement Alert|GRAIL, Inc. Rises 6.76% in Pre-Market Trading, FDA Advisory Committee Favorable Vote on Galleri Continues to Catalyze

Market Focus
·
Oct 06

Grail to Present New NHS-Galleri, Pathfinder 2 Data on Galleri Cancer Test at EDCC, ESMO 2026

Reuters
·
Oct 06

Movement Alert|GRAIL, Inc. Intraday Rise 5.13%, UBS Price Target Hike to $175 Spurs Investor Confidence

Market Focus
·
Oct 05

UBS Adjusts GRAIL Price Target to $175 From $105, Maintains Buy Rating

MT Newswires Live
·
Oct 02

Movement Alert|GRAIL, Inc. Rises 6% in Regular Trading, FDA Advisory Committee Favorable Vote Continues to Drive Stock Rebound

Market Focus
·
Oct 02

Grail Inc : UBS Raises Target Price to $175 from $105

THOMSON REUTERS
·
Oct 02

Grail's Cancer Blood Test Nears Landmark FDA Approval, but Insurance Coverage Looms

Reuters
·
Oct 02

Movement Alert|GRAIL, Inc. Falls 5.07% in Regular Trading, Post-FDA Advisory Committee Rally Triggers Profit-Taking

Market Focus
·
Oct 02

Grail price target raised to $155 from $75 at Guggenheim

TIPRANKS
·
Oct 01

A Cancer Test Has Investors Betting Big. but Will Insurers Pay? - Heard on the Street

Dow Jones
·
Oct 01

Movement Alert|GRAIL, Inc. Rises 5.27% in Regular Trading, FDA Advisory Committee Unanimously Approves Galleri Safety and Supports Approval

Market Focus
·
Sep 30

Movement Alert|GRAIL, Inc. Rises 5.69% in Regular Trading, FDA Advisory Committee Votes in Favor of Galleri Multi-Cancer Detection Test

Market Focus
·
Sep 28

Grail is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Sep 28

Grail price target raised to $150 from $80 at Canaccord

TIPRANKS
·
Sep 28

U.S. Research Roundup-Chevron, Mobility Global, Tesla

Reuters
·
Sep 28

Grail Inc : Canaccord Genuity Raises Target Price to $150 from $80

THOMSON REUTERS
·
Sep 28

Canaccord Genuity Keeps Their Buy Rating on GRAIL Inc (GRAL)

TIPRANKS
·
Sep 28

Grail price target raised to $100 from $65 at Mizuho

TIPRANKS
·
Sep 25